Search
BMY.US: Opdivo positive kidney cancer headline unlikely driven by subgroup as seen in non-squamous l
Bristol-Myers have just announced that their second line kidney cancer study CHECKMATE 025 of Opdivo vs chemo was stopped early, as it has met its primary endpoint of superior overall survival vs standard of care Afinitor. This result is expected given the 25 months of overall survival seen in the phase II single arm study Checkmate 010 which compares very favourably to historical survival seen with chemo of around 16.5 months. We look at the implication for 1st line
